Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Flyte, a regional air mobility subsidiary of VTAK (NYSE American: VTAK), is deploying aircraft across the Northeast to serve peak travel demand for the Preakness Stakes on Saturday, May 16. Centered on Baltimore/Washington International (BWI), the high-frequency short-haul program targets premium, time-sensitive travelers.
Core routes from New York, Boston, Washington, D.C., and Philadelphia, plus expansion routes from Charlotte and Raleigh-Durham, are structured for dense, rapid-cycle schedules aimed at maximizing aircraft utilization and capturing event-driven revenue opportunities.
Flyte (NYSE American: VTAK) is increasing flight capacity and launching a targeted hiring initiative after Spirit Airlines ceased operations on May 2, 2026. Flyte is accelerating its planned Vision Jet fleet expansion, broadening regional route coverage, and opening a structured onboarding pipeline for impacted pilots and aviation professionals.
The company framed these steps as part of its existing growth plan and says they aim to support utilization and service availability amid reduced commercial capacity and tighter fares on certain domestic corridors.
Catheter Precision (NYSE:VTAK) will attend the 47th Heart Rhythm Society meeting in Chicago, April 24–27, 2026, featuring the VIVO system in a poster (April 24) and a core-session presentation (April 25). Two new peer‑reviewed papers for LockeT (139 patients) and VIVO (31 patients, 48 VTs) are published online.
The announcements emphasize feasibility data for intracardiac VT localization, workflow benefits for VT ablation, and LockeT venous‑closure outcomes including high procedural success and low complication rates.
Catheter Precision (NYSE American: VTAK) received a Notice of Allowance from the USPTO on April 21, 2026, for key claims covering its LockeT surgical vessel closing pressure device.
The allowed claims protect both the device architecture and method of use, reinforcing the company’s intellectual property position, creating barriers to entry, and supporting its IP-driven commercialization and growth strategy.
Flyte (NYSE American: VTAK) said it is accelerating expansion in short‑haul regional markets on April 20, 2026, as major airlines cut routes amid rising jet fuel costs and network redeployment. Flyte operates FAA Part 135 service with Cirrus Vision Jets and reports active, revenue‑generating operations to capture displaced demand.
The company positions point‑to‑point, right‑sized flights as a lower‑fuel, high‑frequency alternative in underserved corridors, notably in the Northeast, where airline service is declining.
Catheter Precision (NYSE: VTAK) completed a shareholder-approved acquisition of Fly Flyte on April 15, 2026, making Flyte a wholly owned operating subsidiary. The deal immediately consolidates 100% of Flyte’s revenue, assets, and operations into VTAK and provides direct exposure to cash flow from FAA Part 135 certified regional air services.
The acquisition gives VTAK control of capital allocation, fleet expansion, and a revenue-generating aviation platform positioned for scalable growth in regional air mobility ahead of eVTOL commercialization.
Catheter Precision (NYSE American: VTAK) announced that a VIVO study has been accepted for publication in EP Europace on April 13, 2026. The 31‑patient study mapped 48 VTs and found ECGi mapping with VIVO accurately predicted arrhythmogenic substrate for scar‑dependent VT and may improve procedural efficiency.
The study reported VIVO localization in NICM patients showed 100% specificity and 66.7% sensitivity for epicardial VTs versus a four‑step ECG algorithm (sensitivity 50%, specificity 0%). The company plans a larger multi‑center study later in 2026.
Catheter Precision (NYSE American: VTAK) will attend the annual European Heart Rhythm Association (EHRA) conference in Paris from April 12–14, 2026. The company said it will use the event to share new data, engage key opinion leaders and educate physicians and distributors about LockeT after CE Mark receipt.
This appearance is the company's first large European conference since LockeT received CE Mark clearance and aims to support expanded product use and commercial momentum.
Catheter Precision (NYSE American: VTAK) announced acceptance of a manuscript in the Journal of Interventional Cardiac Electrophysiology on April 6, 2026. The study of LockeT in 139 patients reported high procedural success, rapid hemostasis, early ambulation, and low complication rates for large-bore venous access closure.
The peer-reviewed acceptance supports LockeT as a feasible venous closure strategy in electrophysiology practice and may aid the company’s commercialization and hospital engagement efforts in the US and Europe.
Catheter Precision (NYSE American: VTAK) engaged a strategic advisor on April 2, 2026 to formally market for sale its cardiac electrophysiology business. The process aims to monetize legacy medical device assets (LockeT and VIVO) that have FDA market clearance and the CE mark, while the company sharpens focus on its Flyte aviation platform. Management says the sale could unlock shareholder value and that monetization would position the company as a pure‑play aviation business through disciplined capital allocation and increased execution and transparency.